On April 26, the 14th Chengdu Congress of the Communist Party of China opened. The report of the Party Congress mentioned that it is necessary to unswervingly promote the construction of a strong chain of industrial circles, accelerate the construction of a modern industrial system with outstanding competitive advantages, highlight the development of 100-billion-level industrial clusters such as biomedicine, promote the inheritance and innovative development of traditional Chinese medicine, and make systematic planning and work deployment for relevant key links in the strong chain of industrial circle construction.
Party representatives from the front line of enterprises are particularly concerned about the new opportunities released by the party congress report to the industrial development, and some of the "keywords" in the party congress report are triggering heated discussions among party representatives from the pharmaceutical industry: how to make up for the "key link" of the supply chain, capital chain and innovation chain of the 100-billion-level pharmaceutical industry cluster?
Build a safe and stable supply chain and capital chain of medicinal materials
Build a digital workshop, strengthen and optimize the Sichuan pharmaceutical industry
"The report of the party congress mentioned that accelerating the construction of a healthy Chengdu and promoting the innovation and development of traditional Chinese medicine inheritance, as a party representative from the front line of the enterprise, I feel that the development of traditional Chinese medicine has been paid more and more attention and is very encouraged." After listening to the report of the Party Congress, Wu Dengju, a representative of the 14th Party Congress of Chengdu and secretary of the Party Committee of Sichuan Everbright Pharmaceutical Co., Ltd., is full of expectations for the development of the Traditional Chinese medicine industry.
▲ Wu Dengju, deputy to the 14th Party Congress of Chengdu
Another work that is being promoted also makes her full of expectations for the cause of traditional Chinese medicine she is engaged in, "The new factory invested by the company is grabbing the construction period, progressing smoothly, the cumulative investment of this project is more than 600 million yuan, it is expected to be completed at the end of December this year, and it will be settled in March next year, and this project will also be integrated into the Chengdu industrial construction circle strong chain action." ”
In the face of the future, there are new opportunities for development, and the current Chinese medicine industry is also facing some "growing pains". "There are not many chinese medicine categories with a single variety output value of more than 100 million yuan in Chengdu" "The level of automation control of the whole process of the local Chinese medicine pharmaceutical industry still needs to be improved, especially the pace of digital factory construction needs to be accelerated"... When it comes to the development of the Traditional Chinese medicine industry, Wu Dengju is both excited and has hidden worries in her heart.
"The traditional Chinese medicine industry chain includes the supply of medicinal materials, research and development and production, etc., and on the upstream supply side, Chengdu should further enhance the supply capacity of medicinal materials." Wu Dengju introduced that her Everbright Pharmaceutical has created a solid upstream supply chain through self-construction, co-construction and other forms, "We have more than 100 categories of traditional Chinese medicine, it is impossible to achieve complete self-cultivation of medicinal materials, the company has laid out a medicinal material procurement base throughout the country, and also built a medicinal material base in the form of cooperation with farmers." The harvest of medicinal herbs can be affected by many factors, and it is crucial for companies to create a stable and controllable supply chain. ”
The report of the Party Congress pointed out that promoting the high-end, intelligent and green transformation of the manufacturing industry has made Wu Dengju see greater prospects for the Traditional Chinese medicine pharmaceutical industry. "However, the degree of automation of local Chinese medicine pharmaceutical companies needs to be improved." She suggested that Chengdu should speed up the quality and growth rate of the Sichuan pharmaceutical industry, strengthen and optimize the Sichuan pharmaceutical industry, and vigorously invest in equipment upgrading and technological improvement.
"The level of automation in the manufacturing of traditional Chinese medicine is directly related to the production efficiency and safety of the company's products, the production links of drugs are particularly strict, there can be no flaws, the level of informatization and intelligence of the process should be improved, the automation control of the whole process of production should be realized, the whole production cycle data is monitored in real time, and the whole process can be traced, so as to accelerate the cultivation of leading enterprises in Sichuan medicine and enhance the market influence of Sichuan medicine brands." Wu Dengju said frankly that due to the large investment in equipment, the capital chain of the enterprise's industrial technological transformation cannot be broken, and it is expected that Chengdu will introduce targeted financial measures to encourage more enterprises to promote digital and intelligent construction and achieve green production.
How to solve the problems in the early stage of achievement transformation?
Make it possible to "10 platforms serve 100 enterprises"
Xia Xinyi, representative of the 14th Party Congress of Chengdu and assistant general manager of Chengdu Nuohe Shengtai Biotechnology Co., Ltd., shared some industry information at the group discussion during the party congress, and the party congress report made her have more expectations for the development of innovative drugs: "Biomedicine research and development cycle is long, large investment, is a long-term insistence on the cause, need policy, technology, talent, capital, market, service and other aspects of support. ”
▲ Xia Xinyi, deputy of the 14th Party Congress of Chengdu
A clear positive, let Xia Xinyi feel that the vision that she and the company team had been looking forward to was expected to be realized ahead of schedule. The report of the party congress mentioned that it is necessary to accelerate the cultivation and development of industrial ecology, support key enterprises and colleges and universities to jointly build and share public technology platforms such as pilot production and testing, and encourage and guide professional service institutions such as industry alliances and industry business associations to coordinate investment promotion and resource sharing.
"For biomedical enterprises, pilot scale-up is the only way to achieve the transformation of achievements, and the report of the Party Congress especially mentions the 'shared public technology platform such as pilot testing and testing', which once created, can bring a comprehensive, efficient and professional service experience to the transformation of enterprise achievements, and accelerate the process of pharmaceutical research and development projects to marketization." Xia Xinyi said.
In 2018, Chengdu Novo Shengtai landed in Chengdu Tianfu International Bio-City, focusing on the field of peptide drugs. "At present, some innovative drug products are about to enter the research stage of GLP (Note: in line with the "Good Management Practice for Non-Clinical Research of Drugs"), which involves the pilot link, and we have laid out tens of thousands of square meters of GMP (Note: in line with the "Good Manufacturing Practice for Drugs") production workshop in Chengdu Tianfu International Bio-City, which can meet both future production and pilot tests." In Xia Xinyi's view, standing at the level of the entire industry, a problem is worth paying attention to, "How to solve the problem of pilot amplification of the biomedical innovation and entrepreneurship team, open up the bottleneck of the initial landing of the transformation of the results, so as to seamlessly integrate the industrialization?" This requires a public technology platform that integrates resources such as pilot testing and testing. ”
"Especially for start-up enterprises, the early stage is often the main focus on technology research and development, R & D funds accounted for a relatively large proportion, and the pilot is a key part of the innovation chain, through the government department to create a public technology platform that gathers multi-party high-quality resources, and adopt an enterprise operation mode, so that biomedical companies can smoothly carry out pilot, testing and other businesses here." Xia Xinyi said that the public technology platform can reduce the cost of the enterprise's self-built pilot platform, from the perspective of industry development, it will bring about the effect of resource agglomeration and avoid the waste of resources in the entire industry, "Just imagine, in the past, 100 companies may build 100 pilot platforms, after building some public technology platforms, perhaps 10 platforms can serve 100 enterprises and achieve the role of point and surface." ”
In the innovation chain of pharmaceutical companies, Xia Xinyi also mentioned a phenomenon worthy of attention, "In fact, many reagent consumables in the research and development process of local pharmaceutical companies mainly come from outside the province, such as Suzhou and Shanghai, and we are also looking for local suppliers who can meet alternative conditions, and look forward to Chengdu enterprises making breakthroughs in this regard in the future and forming an upstream and downstream supply chain nearby." ”
Red Star News reporter Ye Yan and Song Jia asked
Edited by Yixi Chen